Download investor letter here

Download the minutes here

Download notice here

Unblinding of the database after SER150 CL-009 was delayed. Calculation of SER150 effect on kidney function compared to placebo is consequently also delayed. Read more here

Contacts to banks for assisting Serodus in selling Serodus AS, the pipeline or the individual assets was initiated. Database for SER150 CL-009 is expected to be unblinded late August or…

Download the minutes here

Read more here

Serodus ASA - Publishes 2023 Annual Report Download it here

As a consequence of Board decision in December 2023, screening of new patients is stopped. The last patient last visit will be August 2024. Report expected to be finalized in…

After an initial increasing in screening and randomization activities of patients to the SER150 CL-009 study in New Zealand this has slowed down. Recruitment of patients in Australia remains very…